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TBE, and salmonellosis are likely to be majorly affected by climate change.
CONCLUSIONS: Accelerating climate change carries a profound threat for the in-
creased burden of infectious diseases worldwide. To attain the maximum disease
prevention, an understanding of the ecology of infectious diseases must be devel-
oped in order to protect vulnerable populations, rather than focussing on single
agent of disease.
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OBJECTIVES: To forecast and better understand the primary drivers of the inci-
dence and prevalence of andmortality from drug sensitive andmultidrug resistant
tuberculosis (DS-TB and MDR-TB, respectively).METHODS: The Tuberculosis Sim-
ulation Model (TBSM) is a dynamic disease simulation model that uses historical
and current disease incidence, treatment success rates, mortality, and transmis-
sion trends and can account for expected market events to estimate future DS-TB
and MDR-TB incidence, prevalence and mortality in China. RESULTS: The model
shows that between 2010 and 2050, DS-TB incidence, prevalence andmortality will
decrease by 29%, 52% and 29%, respectively, whereas MDR-TB incidence, preva-
lence and mortality will fall by 3%, -11% and 10%, respectively. These reductions
would be driven by an expected decrease in the pool of people with latent infection
(brought about by improved cure rates which in turn reduces transmission rates)
and reduced rate of progression from latent to active TB. CONCLUSIONS: Results
from this model demonstrate considerable anticipated decreases in DS-TB and
MDR-TB incidence and mortality in China over the next forty years; the decreases
are much larger for DS-TB than for MDR-TB. Improvements in MDR-TB diagnosis
and improved cure rates due to betterMDR-TB treatments can likewise be expected
to decrease MDR-TB incidence, prevalence and mortality over the long run. This
adaptable TBSM tool has potential value in public health practice by forecasting
outcomes of interventions and can also be useful for cost effectivenessmodeling by
country or by region by defining critical unmet need.
INFECTION - Cost Studies
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OBJECTIVES: To compare direct health care costs of treatment experienced pa-
tients with HIV/AIDS before and after triple class failure across participating
centers.METHODS: The resource use data for eligible patients were collected two
years before, and  90 days following the date of triple class failure (TCF), which
was between January 2002 and June 2008. The treatment failure was defined as
virological failure to at least one drug from each of three classes (NRTI, NNRTI and
PI). Costs of resource use at patient levelwere estimated bymultiplying the number
of resources used by the national micro-costing-based estimates. Comparisons of
log-transformed expenditure data for the first 3, 6, 12 and 24 months before TCF
with their corresponding intervals after TCF were carried out using linear mixed
model. RESULTS:Of 42 patients recruited,mean agewas 38 years andmajority was
male (66.7%). Outpatient visit expenditure after TCF was significantly 78.767.34,
78.2613.28 and 683.0090.21 baht higher than that before TCF during the first 3, 6
and 24months respectively (P0.001,0.003, and0.001, respectively). Compared
with before TCF, expenditures on direct HIV lab tests (CD4/viral load/genotyping)
after TCF were significantly 5133.74661.80, 6907.23742.23, 7505.29981.76 and
9069.931219.37 Baht higher at the first 3, 6, 12 and 24 months, respectively
(P0.001, 0.001, 0.001, and 0.004, respectively). Expenditures on antiretroviral
medications after TCFwere also higher althoughwith significance only for the first
24 months (148414.0632322.67 baht higher, P0.007) and with borderline signifi-
cance for the first 3, 6 and 12months. Finally, overall direct expenditures after TCF
were significantly higher than those before TCF in all 4 periods. CONCLUSIONS:
Once triple class failure occurred, overall direct expenditures increased signifi-
cantly as early as 3 months and through 2 years of follow-up. The most dramatic
increase was the costs associated with laboratory tests, especially genotyping, and
outpatient visits.
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OBJECTIVES: Older adults are in an increasing risk of pneumococcal diseases, in-
cluding meningitis and bacteremia (invasive pneumococcal disease, IPD), and
pneumonia. The objective of this study was to estimate the clinical and economic
burden of pneumococcal disease in adults 50 years of age in Taiwan.METHODS:
Cases of hospitalized IPD and cases of hospitalized and outpatient pneumonia
were obtained by ICD-9 codes from Taiwan’s National Health Insurance Reim-
bursement Database from 2002-2009. Pneumococcal pneumonia was assumed to
comprise 23.8% of all-cause pneumonia based on published literature. Data were
stratified by age groups 50-64, 65-74, 75-84 and 85. Average incidence rates were
calculated by dividing cases by age group and year specific population figures. Cost
was extracted from the database for inpatient and outpatient cases; mortality es-
timation was based on hospital mortality. RESULTS: The average incidence per
100,000 person years was 2.4 for IPD, 278.8 for hospitalized pneumococcal pneu-
monia, and 1376.4 for outpatient pneumococcal pneumonia. Mortality was 12.2%
for IPD and 10.0% for hospitalized pneumonia. Comparedwith adults 50-64 years of
age, the incidence of pneumococcal hospitalization were 3.7 fold higher in those
65-74, 9.7 fold higher in 75-84 and 19.5 fold higher in those 85. The total number
of hospitalizations increased by 20% from 2002 to 2009, largely attributable to pop-
ulation growth. In 2009, there were 16,711 pneumococcal hospitalizations, 103,302
outpatient visits, and 1,920 deaths, with a total cost of NT$ 2.92 billion. Hospitalized
pneumococcal pneumonia was responsible for 94% of costs and 99% of mortality.
CONCLUSIONS: The morbidity and mortality of pneumococcal disease increases
sharply with advancing age, signaling an increasing public health problem in older
adults as the population ages. Expanded utilization of cost-effective treatment and
prevention efforts are warranted to alleviate the burden of pneumococcal diseases
in Taiwan.
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OBJECTIVES: To estimate direct medical cost and productivity lost for invasive
pneumococcal diseases in child under 2 in urban China. METHODS: Six health
status contained pneumococcal meningitis (inpatient), pneumococcal septicemia
(inpatient), pneumonia (all-cause, inpatient), pneumonia (all-cause, outpatient),
mild otitis media (all-cause,outpatient) and sever otitis media (all-cause, outpa-
tient )were considered. Age-specific cost was collected from electronic patient re-
cords (2010) from 14 hospitals in 7 cities in China. 2 hospitals in each city was
selected (1 Children’s Hospital, 1 Comprehensive Hospitals) and 7 field cities in-
cluding Beijing, Guangzhou, Shenzhen, Wuhan, Xi’an, Chengdu and Shenyang
were enrolled. Directmedical cost included registry fee, medications, and diagnos-
tic tests fee, hospitalization expenditure. Cost of productivity lost were days for
work absent of patient plus time consumed of infirmaries. In first part, weighted
average method was used to calculate average direct medical cost. In second part,
daily wage rate was applied to estimate cost of productivity lost. RESULTS: The
average direct medical cost in all IPD cases (pneumococcal meningitis& pneumo-
coccal septicemia) was 20,950 Yuan (95%CI: 4,489-101,003). Average 19 working
days lost in patients’ relatives for caring and costs of productivity lost was 1934
Yuan (95%CI: 532-6,412) per patient. CONCLUSIONS: IPD has a serious impact on
life quality of child under 2 in Chinese urban areas and it could lead to severe
economic burden.
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OBJECTIVES: To analyze the inpatient direct medical costs of pneumonia among
regions, level of cities, and types of the hospitals. Difference of reimbursement rate
between the Urban Employee Basic Medical Insurance (UEBMI) and Urban Resident
Basic Medical Insurance (URBMI) plans were compared. METHODS: Systematic
sampling was used to collect data on inpatients costs of pneumonia in 2009 in
China. The database includes 2868 hospitals from 60 cities. Direct medical costs of
inpatients with pneumonia and reimbursement rate between UEBMI and URBMI
planswere analyzed. RESULTS: In 2009, pneumonia was themost frequent disease
in children below 5 years old and 5th among people 6 to 65 years old in China. In
total 210,421 hospitalization case, the average cost of inpatient pneumonia was
5,415 Yuan ($853) per patient, and the expense in capital cities, prefectural-level
cities, and county-level cities were 16,375 Yuan ($2,579), 4,321 Yuan ($681), and
4,434 Yuan ($698), respectively. The average length of hospitalizationwas 14.6 days
for patients covered with UEMBI, and 11.7 days for those covered with URMBI.
Almost 67% of the direct medical costs were covered by two medical insurance
systems, but differed by system as 73.35% for urban employees and 51.99% for
urban residents. Patients below 5 years old paid 64.76% of the direct medical costs
out of pocket, whereas people over 65 year old only paid 27.2% because they were
shielded by two different systems. CONCLUSIONS: In China, pneumonia is a com-
mon disease that mainly affects children and elderly people. There was significant
difference in directmedical costs and the length of hospitalization among different
regions and medical insurance systems. Costs in big cities were much higher than
smaller ones because of the unbalanced distribution and uneven economics situ-
ation. The reimbursement rate of URMBI was much lower than that of UEMBI.
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OBJECTIVES: Nosocomial infection can occur more frequently in patients on ad-
mission to the hospital. Patients must result in a longer treatment stays, and in-
crease costs from the use of antibiotics to treat patients. The purpose of this study
was aimed to calculate the value of antibiotics used to treat patients with nosoco-
mial infections in inpatient department at Nakhon Pathom hospital. METHODS:
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The data collection of antibiotic use’s expenditure for nosocromail infection treat-
ment at in-patient department was performed between 1 January 2010 to 30 June
2010. The source of information came from Infectious Control division of the hos-
pital. All information were recorded further source such as in-patient data-based
was used if the information of former source was incompleted. RESULTS: The
analysis showed that patients with nosocomial infection is 314 patients (141
male,173 female). Themost age of infection is between 71-80 years (31.53%). Build-
ing that has the most infected frequency is female medicine building (infected 35
patients (11.15%)).The most common pathogen is Acinetobacter baumannii-MDR
(25.34%) while the most origin of infection is lower respiratory tract (62.80%). Du-
ration of admission in hospital until the occur of nosocomial infection is during the
first 10 days (32.80%).The value of all antibiotics used to treat patients is
12,354,176.50 bath and the cost of eachmonth as shown in Figure 1. Sulbactam and
Cefoperazone (Sulperazon®) is themost highest cost, our data is similar trend from
previous study in other setting. Figure 1 Cost of antibiotics used in each month
(data for 6months).CONCLUSIONS: From the information obtained from this study
will make the hospital concern about strategies to prevent nosocomial infection to
reduce the loss of various and enhance the quality of life for patients.
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OBJECTIVES: to obtain information on the cost of treatment (outpatient and inpa-
tient care), including laboratory, drugs,medical supplies, consultation, Xray, room.
METHODS: A crosssectional study was done to collect data in public hospital in
East Java. Samples were 89 cases IDU with HIV, 49 of them received inpatient care.
Substitution for IDUwas not included in the study. RESULTS: Increasing number of
IDU and HIVAIDS cases in Indonesia (one province with high cases is East Java) has
lead the policy makers to provide subsidy for people living with HIVAIDS. Little is
known about the cost of treatment in hospital. It is important for both payer and
hospital to understand how best the provider payment scheme to provide services
for PLHIV. The study revealed that most of them were men, at productive age, and
come from both urban and rural area. Only 25% of them has less than 3 diagnosis
(opportunistic infection), and the rest are having more than 3 diagnosis. The top
three cases were Lung disorder, GastroEnteritis and Candidiasis. Sixty-two% of
them discharged with better condition, but 35% died. Average Length of stay was 9
days, and some of them were hospitalized more than one month. Average cost for
inpatient care was USD 547 perday and outpatient care was USD 61 for one visit.
Medical exam, drugs andhotel costswere having highest proportion. This situation
was hard for the poorwhile hospital felt total costs were not sufficiently covered by
government financing scheme for the poor. CONCLUSIONS: Cost of tretament for
PLHIV is high and in the future become serious burden for both payer and provider.
Payment to provider should consider the cost of tretament.
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OBJECTIVES: This review aimed to explore the research situation in Southeast Asian
countries on the economic evaluationof vaccination.METHODS:Asystematic literature
search was conducted in March 2012 using the Medline electronic database with the
PubMed interface. The search was limited to English-language articles published during
2001–2012. Keywords of “(analy* OR evaluat*) AND (vaccin* OR immuni*) AND (‘region/
country names’)” were employed. Themethodological quality of the studywas assessed
against the CHEC criteria list. RESULTS: Out of 1344 articles, 27 eligible articles were
retrieved and reviewed. It was found that the studies had been conducted in seven of
eleven countries in the region. Thailand had the greatest number of publications (10).
Twelve articles (44%) were written by local researchers, 19% by outside researchers, and
37% in collaboration of both. Among the articles, 56% mentioned the name of a local
researcheras thefirst or correspondingauthor. Thenumberof articles tended to increase
yearly. The types of vaccination included in the studieswere dengue, HPV, Hib, Hepatitis
A and B, HIV, influenza, Japanese encephalitis, PCV, rotavirus and varicella. Most of the
publications dealt with HPV (6) and rotavirus (6). Three studies evaluated a vaccination
program that was included in the NIP of the particular country (hepatitis B in Thailand,
and influenza and PCV in Singapore). All of the studies employed modeling. The most
frequent category of evaluation was CUA (56%), followed by CEA (15%) and CBA (11%).
Most of the studiesmet a brief CHEC criteria list, such as study population, time horizon,
perspective, discounting, and sensitivity analysis. CONCLUSIONS: An analysis was
conducted of publications focusing on the economic evaluation of vaccination in
Southeast Asian countries. Most studies were conducted by local researchers. It
can be assumed that such economic information is gaining importance in policy
decision making.
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OBJECTIVES: This study aims to assess the cost-effectiveness of rotavirus immu-
nization in Indonesia, taking breastfeeding patterns explicitly into account.
METHODS: An age-structured cohort model was developed for the 2011 Indonesia
birth cohort. Next, we compared two strategies, the current situation without ro-
tavirus immunization versus the alternative of a national program. The model
applies a 5 years time horizon, with 1month analytical cycles for children less than
1 year of age and annual cycles beyond 1 year. Four scenarios were compared:
population under 1 year oldwith 100%exclusive breastfeeding, 100%partial breast-
feeding, 100% no breastfeeding and the actual combination over the different
breastfeeding modes as present in Indonesia currently. Monte Carlo simulations
were used to examine the economic acceptability and affordability of the rotavirus
vaccination. RESULTS: Rotavirus immunization would effectively reduce severe
cases of rotavirus during the first 5 years of life. Under the GAVI-subsidized vaccine
price the vaccine cost would amount to US$ 3.7 million per annum. The incremen-
tal cost per quality-adjusted-life-year (QALY) in the base case was US$ 271 from
health care perspective; much lower than the Gross Domestic Product (GDP) per
capita of US$ 3.469 in 2011. Affordability results showed that at the GAVI-subsi-
dized vaccine price, rotavirus vaccination could be affordable for the Indonesian
health system. Vaccination is most cost-effective in case of 100% no breastfeeding.
CONCLUSIONS: Rotavirus immunization in Indonesia would be a cost-effective
health intervention with GAVI’s financial support. The results showed that rotavi-
rus immunization would greatly reduce the burden of disease due to rotavirus. It
also showed that no breastfeedingwouldmake vaccination themost cost-effective
intervention comparing to other two breastfeeding patterns.
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Streptococcus pneumonia has caused invasive diseases as meningitis and bacte-
remia and non-invasive diseases as pneumonia and acute otitis media (AOM),
leading to high morbidity and mortality in infants and the elderly in Hong Kong.
OBJECTIVES: To examine the health and economic impact of pneumococcal non-
typeable haemophilus influenza protein-D conjugate vaccine (PHiD-CV) in the pub-
lic sector of Hong Kong compared to no vaccination. METHODS: A transmission
dynamic model adapted with local data was developed to simulate multiple age-
specific cohorts progressingwith invasive pneumococcal diseases (IPD) (meningitis
and bacteremia), all-cause pneumonia, and acute otitis media (AOM) over 10 years
assuming annual universal vaccination on newborn infants with coverage rate of
90%. The study was performed from a health care payer’s perspective. Epidemio-
logical and cost data inputs were based on previously published study. Direct vac-
cine effectiveness was estimated from prior clinical trials and post-marketing
studies. 1-way and multivariate probabilistic sensitivity analyses were performed
to test the robustness ofmodel outcomes. 3%discount ratewas applied to both cost
and effectiveness. RESULTS: Model projections predicted that universal infant
PHiD-CV vaccination could prevent 74 deaths (1,553 quality-adjusted life years)
caused by IPD and hospitalized pneumonia. PHiD-CV was projected to prevent 555
additional cases of IPD, 19,706 cases of hospitalized pneumonia and 29,974 AOM
over 10-year horizon as compared with no vaccination. Assuming vaccine price of
HK$265 (including administration cost of HK$70) per dose, PHiD-CV vaccination is
estimated to save an additional HK$799.65 millions as compared with no vaccina-
tion at the total vaccination cost of HK$66.18 millions. CONCLUSIONS: PHiD-CV is
expected to have great impact in alleviating pneumococcal disease burden and to
spare considerable disease management cost in treating pneumococcal diseases.
In all, universal infant PHiD-CV vaccination is a cost-saving strategy.
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OBJECTIVES: To analyze AMR in Thailand. METHODS: A systematic review over the
period 1980 to present under the PRISMAguidelinesusing 4databases: Pubmed; Science-
direct;Healthsystemresearchinstitute (HSRI)ofThailand;andThai journalcitationindex
centre (TCI). Key words used were [health care-associated OR nosocomial OR hospital
acquired AND Economic* AND Thai*] AND [antimicrobial resistan* AND Thai*]. We also
used key words in Thai language for Thai databases. Inclusion criteria: epidemiologic
studies andpharmacoeconomic studies of bacterial resistanceofnosocomial infection in
Thailand. Exclusion criteria: pharmacokinetics, pharmacodynamics, pharmacologics,
molecularandgenomicsstudies.Studies inagriculturesandlivestockwerealsoexcluded.
RESULTS: Nineteen studies met eligible criteria in this systematic review. There
were 4 groups of study onAMR burden and situation. Theywere: 1) AMR situations:
a systems analysis; 2) AMR burden: epidemiological burden such as surveillance
studies fromNational Antimicrobial Resistance Surveillance Thailand (NARST) and
national surveillance of nosocomial infections in Thailand from 1988-2006 and
economics burden; 3) factors associated with AMR in Thailand; and 4) studies of
AMR preventions and control programs in Thailand. CONCLUSIONS: AMR is one of
themajor health problems in Thailand. The existing data lack clarity and are often unre-
liable toquantify anaccurate amount ofAMRburden.More valid and reliable data on the
use of antimicrobials and of AMR aswell asmorbidity andmortality data related to AMR
areneeded inorder to computeburdenofAMR inThailandat anational level and inform
policy decisionmaking.
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